

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information



HOME

PREVIOUS


NEXT

THE SKELETON is a dynamic organ that is constantly regenerating. Bone is made up of a matrix and highly specialized cells, including osteoblasts, osteoclasts, osteocytes, and bone lining cells.¹ These specialized cells carry out bone modeling and remodeling in a tightly regulated process that maintains the integrity of bone. Numerous factors regulate the activity of osteoblasts and osteoclasts in bone modeling and remodeling.² An imbalance or alteration in these pathways may lead to increased bone loss and contribute to the pathogenesis of osteoporosis.³

Femur Head



BONE MATRIX COMPONENTS



BONE REMODELING PROCESS		
Premenopausal	Postmenopausal Osteoporosis	SHOW ALL PATHWAY ARROWS

1. Manolagas SC. *Endocr Rev.* 2000;21:115-137.
 2. Raggatt LJ, et al. *J Biol Chem.* 2010;285:25103-25108.
 3. Raisz L. *J Clin Invest.* 2005;115:3318-3325.

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information

HOME


PREVIOUS

NEXT

Premenopausal Bone Remodeling

Normal bone remodeling before the menopause consists of five main phases:

- *Activation phase:* Osteoclast precursors differentiate into osteoclasts which are recruited to the remodeling site¹
- *Resorption phase:* Osteoclasts resorb bone at the site of remodeling¹
- *Reversal phase:* After resorption, the osteoclasts undergo apoptosis and osteoblasts are recruited¹
- *Formation phase:* Osteoblasts lay organic bone matrix which later undergoes mineralization¹
- *Resting phase:* Bone lining cells remain dormant until the next cycle of remodeling starts²



1. Langdahl B, et al. Ther Adv Musculoskelet Dis. 2016;8:225-235.
2. Raggatt LJ, et al. J Biol Chem. 2010;285:25103-25108.

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information

HOME

PREVIOUS


NEXT

Postmenopausal Osteoporosis Bone Remodeling

Estrogen deficiency during menopause greatly affects bone turnover cycle. Osteoclast resorption activity increases while the activity of osteoblasts decreases. This results in more resorption than deposition of bone, leading to net bone loss¹

Postmenopausal women undergo two stages of bone loss. During the first, trabecular bone is predominantly affected, where bone resorption exceeds bone formation, called menopause-related bone loss. During the second, there is slower persistent loss of both trabecular and cortical bone, caused by reduced bone formation, called age-related bone loss¹

Not all postmenopausal women develop osteoporosis. Bone mineral density (BMD) is used to identify osteoporosis and fracture risk. An individual's BMD is compared to the mean value in young healthy individuals. A standard deviation value between -1 to +1 indicates normal bone, while a value between -1 and -2.5 indicates osteopenia and ≤ -2.5 indicates osteoporosis²



BONE REMODELING PROCESS		
Premenopausal	Postmenopausal Osteoporosis	SHOW ALL PATHWAY ARROWS

1. Ji MX, et al. *Chronic Dis Transl Med.* 2015;1:9-13.
 2. U.S. Department of Health and Human Services. *Bone Health and Osteoporosis: A Report of the Surgeon General.* 2004.

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information

HOME


PREVIOUS

NEXT

Parathyroid Hormone


Parathyroid hormone (PTH) is secreted by the parathyroid gland and maintains calcium homeostasis¹

Endogenous PTH stimulates both bone formation and bone resorption¹



Adapted from Blau JE, et al. *Rev Endocr Metab Disord.* 2015;16:165-174.
*FGF-23 suppression on the parathyroid gland was reported in in vitro studies only

1. Bergwitz C, et al. *Ann Rev Med.* 2010;61:91-104.



BONE REMODELING PROCESS		
Premenopausal	Postmenopausal Osteoporosis	SHOW ALL PATHWAY ARROWS

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information

HOME


PREVIOUS

NEXT

Calcium / Vitamin D


Calcium homeostasis is regulated by parathyroid hormone (PTH) and maintained by absorption of dietary calcium in the intestine, reabsorption in the kidney, and release from bone¹

Vitamin D indirectly acts on bone homeostasis by suppressing PTH and increasing intestinal absorption of calcium and phosphate¹



Adapted from Blau JE, et al. *Rev Endocr Metab Disord.* 2015;16:165-174.
*FGF-23 suppression on the parathyroid gland was reported in in vitro studies only

1. Lieben L, et al. *Best Pract Res Clin Endocrinol Metab.* 2011;25:561-572.



BONE REMODELING PROCESS		
Premenopausal	Postmenopausal Osteoporosis	SHOW ALL PATHWAY ARROWS

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information

HOME

PREVIOUS



NEXT

Phosphate

Phosphate homeostasis is maintained by absorption of dietary phosphate in the intestine, excretion by the kidney, and movement of phosphate between the extracellular space and the bone and soft tissue¹

The majority of phosphate retained in the body is deposited in bone as calcium-phosphate hydroxyapatite crystals²

Chronic serum phosphate deficiency results in impaired bone mineralization, rickets, and osteomalacia¹



BONE MATRIX COMPONENTS

BONE REMODELING PROCESS		
Premenopausal	Postmenopausal Osteoporosis	SHOW ALL PATHWAY ARROWS

1. Berndt T, et al. *Annu Rev Physiol.* 2007;69:341-359.
2. Farrow EG, et al. *Nat Rev Nephrol.* 2010;6:207-217.

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information

HOME

PREVIOUS


NEXT

Estrogen

Estrogen regulates bone metabolism by inhibiting bone remodeling, stimulating osteoclast apoptosis, and promoting osteoblast survival¹

Estrogen suppresses bone resorption in part through increased osteoprotegerin and decreased RANKL expression by osteoblasts, and by modulating RANK signaling in osteoclasts¹

Estrogen deficiency has been identified as the cause of bone loss in postmenopausal women and aging men¹



BONE REMODELING PROCESS		SHOW ALL PATHWAY ARROWS
Premenopausal	Postmenopausal Osteoporosis	

1. Khosla S, et al. *J Bone Miner Res.* 2011;26:441-451.

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information

HOME



PREVIOUS

NEXT

Osteoblasts

Osteoblasts, which originate from mesenchymal stem cells, synthesize and secrete proteins that regulate extracellular matrix formation and mineral deposition¹

Bone formation begins when osteoblasts lay down osteoid, which becomes mineralized into new bone¹



BONE REMODELING PROCESS

Premenopausal Postmenopausal Osteoporosis

SHOW ALL PATHWAY ARROWS

1. Manolagas SC. *Endocr Rev.* 2000;21:115-137.

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information

HOME



PREVIOUS

NEXT

Osteoprotegerin

Osteoblasts produce a glycoprotein called osteoprotegerin (OPG), which binds to RANKL and prevents it from binding to RANK¹

Estrogen directly influences osteoblastic cells to increase the secretion of OPG and inhibit bone resorption²



BONE MATRIX COMPONENTS

BONE REMODELING PROCESS		
Premenopausal	Postmenopausal Osteoporosis	SHOW ALL PATHWAY ARROWS

1. Hofbauer LC, et al. *JAMA*. 2004;292:490-495.
 2. Hofbauer LC, et al. *Endocrinology*. 1999;140:4367-4370

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information

HOME



PREVIOUS

NEXT

RANKL

Osteoblasts, osteocytes, and T-cells produce RANKL¹, which binds to and activates its receptor, RANK, on immature and mature osteoclasts²

Binding of RANKL to RANK promotes osteoclast formation, function and survival²



BONE MATRIX COMPONENTS

BONE REMODELING PROCESS

Pre-menopausal Postmenopausal Osteoporosis

SHOW ALL PATHWAY ARROWS

1. Nakashima T, et al. *Nat Med.* 2011;17:1231-1234.
 2. Dempster DW, et al. *Clin Ther.* 2012;34:521-536.

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information

HOME


PREVIOUS

NEXT

Osteoclasts

Osteoclasts are large, multi-nucleated cells derived from monocyte/ macrophage precursors¹

Osteoclasts attach to bone matrix, then secrete acid and enzymes that degrade bone¹



BONE REMODELING PROCESS

Premenopausal

Postmenopausal
Osteoporosis

SHOW ALL
PATHWAY
ARROWS

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information

HOME


PREVIOUS

NEXT


Bone Matrix

Osteoblasts secrete collagen, which composes the majority of the organic component of bone¹

The inorganic bone matrix consists primarily of mineralized calcium and phosphate¹



BONE MATRIX COMPONENTS



BONE REMODELING PROCESS		
Premenopausal	Postmenopausal Osteoporosis	SHOW ALL PATHWAY ARROWS

1. Downey PA, et al. *Phys Ther.* 2006;86:77-91.

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information

HOME


PREVIOUS

NEXT

Osteocytes

Osteocytes are terminally-differentiated osteoblasts embedded in the bone matrix¹

Osteocytes respond to mechanical and environmental stimuli to modulate the process of bone formation and resorption¹



BONE REMODELING PROCESS

Premenopausal

Postmenopausal
Osteoporosis

SHOW ALL
PATHWAY
ARROWS

1. Bellido T. *Calcif Tissue Int.* 2014;94:25-34.

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information

HOME

PREVIOUS

NEXT


Wnt

Wnt proteins are key signaling molecules in tissue development and regeneration¹

Wnt binds to co-receptors LRP 5/6 and Frizzled, leading to the recruitment of dishevelled and Axin. This recruitment disrupts Axin-mediated degradation of β -catenin, thereby allowing β -catenin to accumulate in the nucleus and mediate gene transcription resulting in increased bone formation¹

Canonical Wnt signaling increases bone formation through multiple mechanisms:

- increased differentiation of mesenchymal stem cells to osteoblasts²
- increased osteoblast activity³
- stimulation of the conversion of bone lining cells into osteoblasts⁴
- regulation of osteoblast and osteoclast activity via osteocyte signaling⁵



BONE MATRIX COMPONENTS

BONE REMODELING PROCESS

Premenopausal

Postmenopausal
Osteoporosis

SHOW ALL
PATHWAY
ARROWS

1. MacDonald BT, et al. *Dev Cell*. 2009;17:9-26.
 2. Hu H, et al. *Development*. 2005;132:49-60.
 3. Kato M, et al. *J Cell Biol*. 2002;157:303-314.
 4. Nioi P, et al. *J Bone Miner Res*. 2015;30:1457-1467.
 5. Tu X, et al. *Proc Natl Acad Sci*. 2015;112:e478-486.

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information

HOME

PREVIOUS



NEXT

Sclerostin

Sclerostin is a protein secreted predominantly by osteocytes in bone^{1,2}

Sclerostin binds to low density lipoprotein receptor-related proteins (LRP4, LRP5, LRP6) and inhibits canonical Wnt- β -catenin signaling¹

In human disease, loss-of-function mutations in the sclerostin gene (*SOST*) result in high bone mass phenotypes, e.g., sclerosteosis³



BONE REMODELING PROCESS

Premenopausal Postmenopausal Osteoporosis

SHOW ALL PATHWAY ARROWS

1. Choi HY, et al. *PLoS One*. 2009;4:e7390.
 2. Winkler DG, et al. *EMBO J*. 2003;22:6267-6276.
 3. Balemans W, et al. *Hum Mol Genet*. 2001;10:537-543.

PATHWAYS — IN — OSTEOPOROSIS



Select text on the image to access detailed information



HOME

PREVIOUS


NEXT

THE SKELETON is a dynamic organ that is constantly regenerating. Bone is made up of a matrix and highly specialized cells, including osteoblasts, osteoclasts, osteocytes, and bone lining cells.¹ These specialized cells carry out bone modeling and remodeling in a tightly regulated process that maintains the integrity of bone. Numerous factors regulate the activity of osteoblasts and osteoclasts in bone modeling and remodeling.² An imbalance or alteration in these pathways may lead to increased bone loss and contribute to the pathogenesis of osteoporosis.³

Femur Head



BONE MATRIX COMPONENTS



BONE REMODELING PROCESS

Premenopausal

Postmenopausal
Osteoporosis

REMOVE ALL
PATHWAY
ARROWS

1. Manolagas SC. *Endocr Rev.* 2000;21:115-137.
2. Raggatt LJ, et al. *J Biol Chem.* 2010;285:25103-25108.
3. Raisz L. *J Clin Invest.* 2005;115:3318-3325.